PriceTargets.com logo

Veracyte - VCYT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $41.13
  • Forecasted Upside: -2.64%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$42.24 As of 12/17/2024 01:00 AM ET
▼ -1.09 (-2.52%)

This chart shows the closing price for VCYT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Veracyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VCYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VCYT

Analyst Price Target is $41.13
▼ -2.64% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is $41.13, with a high forecast of $50.00 and a low forecast of $28.00. The average price target represents a -2.64% upside from the last price of $42.24.

This chart shows the closing price for VCYT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 contributing investment analysts is to moderate buy stock in Veracyte. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/5/2024The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$38.00 ➝ $37.00
11/18/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$26.00 ➝ $28.00
11/15/2024Wolfe ResearchInitiated CoverageOutperform$50.00
11/8/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$40.00 ➝ $44.00
11/7/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$34.00 ➝ $38.00
11/7/2024UBS GroupBoost TargetBuy ➝ Buy$43.00 ➝ $46.00
11/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$37.00 ➝ $44.00
10/17/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$35.00 ➝ $40.00
10/16/2024UBS GroupInitiated CoverageBuy$43.00
10/10/2024GuggenheimInitiated CoverageBuy$40.00
8/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$31.00 ➝ $37.00
8/12/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$21.00 ➝ $26.00
8/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$27.00 ➝ $31.00
5/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$33.00 ➝ $27.00
4/15/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$32.00 ➝ $28.00
2/26/2024Morgan StanleyLower TargetUnderweight ➝ Underweight$22.00 ➝ $21.00
2/23/2024William BlairReiterated RatingOutperform
2/23/2024Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $33.00
11/10/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$23.00 ➝ $22.00
11/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$35.00 ➝ $30.00
11/8/2023William BlairReiterated RatingOutperform
10/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$37.00 ➝ $32.00
10/10/2023StephensReiterated RatingOverweight ➝ Overweight$34.00
8/9/2023Needham & Company LLCBoost TargetBuy ➝ Buy$34.00 ➝ $35.00
8/9/2023Morgan StanleyBoost TargetUnderweight ➝ Underweight$22.00 ➝ $23.00
2/23/2023Needham & Company LLCBoost TargetBuy$33.00 ➝ $34.00
1/18/2023Raymond JamesDowngradeOutperform ➝ Market Perform
1/4/2023ScotiabankInitiated CoverageSector Outperform$33.00
11/4/2022Morgan StanleyLower TargetUnderweight$23.00 ➝ $22.00
11/4/2022Raymond JamesLower TargetOutperform$31.00 ➝ $27.00
11/3/2022Leerink PartnersBoost TargetOutperform$30.00 ➝ $35.00
11/3/2022Needham & Company LLCBoost TargetBuy$31.00 ➝ $33.00
11/2/2022William BlairReiterated RatingOutperform
8/4/2022Raymond JamesBoost TargetOutperform$30.00 ➝ $31.00
8/3/2022Needham & Company LLCBoost TargetBuy$26.00 ➝ $31.00
5/4/2022Needham & Company LLCLower Target$31.00 ➝ $26.00
3/15/2022Needham & Company LLCLower TargetBuy$35.00 ➝ $31.00
3/2/2022StephensLower TargetOverweight$52.00 ➝ $44.00
3/1/2022Lake Street CapitalLower Target$95.00 ➝ $50.00
3/1/2022Needham & Company LLCLower Target$55.00 ➝ $35.00
3/1/2022Raymond JamesLower TargetOutperform$62.00 ➝ $34.00
3/1/2022Leerink PartnersLower TargetOutperform$45.00 ➝ $40.00
1/7/2022StephensInitiated CoverageOverweight$52.00
11/18/2021The Goldman Sachs GroupInitiated CoverageBuy$59.00
11/10/2021William BlairReiterated RatingOutperform
11/10/2021Raymond JamesBoost TargetOutperform$50.00 ➝ $62.00
7/30/2021Morgan StanleyLower TargetUnderweight$45.00 ➝ $42.00
7/30/2021Needham & Company LLCBoost TargetBuy$54.00 ➝ $55.00
7/30/2021Leerink PartnersBoost TargetOutperform$55.00 ➝ $60.00
7/14/2021Leerink PartnersLower TargetOutperform$65.00 ➝ $55.00
6/28/2021Raymond JamesBoost TargetOutperform$45.00 ➝ $50.00
6/25/2021Needham & Company LLCReiterated RatingBuy
6/15/2021Raymond JamesInitiated CoverageOutperform$45.00
5/27/2021William BlairReiterated RatingBuy
5/18/2021Truist FinancialLower TargetBuy ➝ Buy$84.00 ➝ $55.00
5/12/2021Morgan StanleyLower TargetUnderweight$65.00 ➝ $45.00
5/11/2021Leerink PartnersLower TargetOutperform$75.00 ➝ $65.00
5/11/2021Needham & Company LLCLower TargetIn-Line ➝ Buy$88.00 ➝ $54.00
4/27/2021Leerink PartnersLower TargetOutperform$85.00 ➝ $75.00
4/14/2021Needham & Company LLCReiterated RatingBuy$88.00
2/25/2021Morgan StanleyBoost TargetUnderweight$35.00 ➝ $65.00
2/18/2021Leerink PartnersBoost TargetOutperform$83.00 ➝ $85.00
2/8/2021Leerink PartnersBoost TargetOutperform$40.00 ➝ $83.00
1/27/2021Truist FinancialInitiated CoverageBuy$61.00
12/17/2020Lake Street CapitalBoost TargetBuy$40.00 ➝ $60.00
12/17/2020BTIG ResearchBoost TargetBuy$42.00 ➝ $56.00
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$48.00
11/4/2020BTIG ResearchBoost TargetBuy$38.00 ➝ $42.00
11/3/2020Needham & Company LLCBoost TargetBuy$37.00 ➝ $40.00
11/3/2020Leerink PartnersBoost TargetOutperform$37.00 ➝ $40.00
11/2/2020William BlairReiterated RatingOutperform
10/2/2020Needham & Company LLCReiterated RatingBuy$37.00
9/9/2020Morgan StanleyInitiated CoverageUnderweight$35.00
7/31/2020Lake Street CapitalBoost TargetBuy$35.00 ➝ $40.00
7/31/2020Needham & Company LLCBoost TargetBuy$30.00 ➝ $37.00
7/31/2020Leerink PartnersBoost TargetOutperform$32.00 ➝ $37.00
5/7/2020Leerink PartnersBoost TargetOutperform$29.00 ➝ $32.00
5/7/2020Needham & Company LLCReiterated RatingBuy$30.00
2/26/2020Needham & Company LLCLower TargetBuy$34.00 ➝ $30.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.25 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/22/2024
  • 13 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 17 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 14 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
10/19/2024
  • 15 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 34 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 34 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Veracyte logo
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $42.24
Low: $42.09
High: $43.33

50 Day Range

MA: $38.07
Low: $31.92
High: $44.40

52 Week Range

Now: $42.24
Low: $18.61
High: $46.00

Volume

726,627 shs

Average Volume

768,880 shs

Market Capitalization

$3.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Veracyte?

The following sell-side analysts have issued stock ratings on Veracyte in the last twelve months: Guggenheim, Leerink Partners, Morgan Stanley, Needham & Company LLC, Scotiabank, The Goldman Sachs Group, Inc., UBS Group AG, William Blair, and Wolfe Research.
View the latest analyst ratings for VCYT.

What is the current price target for Veracyte?

0 Wall Street analysts have set twelve-month price targets for Veracyte in the last year. Their average twelve-month price target is $41.13, suggesting a possible downside of 2.6%. Wolfe Research has the highest price target set, predicting VCYT will reach $50.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $28.00 for Veracyte in the next year.
View the latest price targets for VCYT.

What is the current consensus analyst rating for Veracyte?

Veracyte currently has 1 sell rating, 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VCYT.

What other companies compete with Veracyte?

Other companies that are similar to Veracyte include Hims & Hers Health, Guardant Health, Option Care Health, Sotera Health and BrightSpring Health Services. Learn More about companies similar to Veracyte.

How do I contact Veracyte's investor relations team?

Veracyte's physical mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 243-6300 and its investor relations email address is [email protected]. The official website for Veracyte is www.veracyte.com. Learn More about contacing Veracyte investor relations.